Fecal microbiota transplantation for management of Clostridium difficile infection

Chetana Vaishnavi1

  • 1Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160 012, India, cvaishnavi@rediffmail.com.

Insights

Fecal microbiota transplantation (FMT) offers a promising alternative to antibiotics for recurrent Clostridium difficile infection (CDI). This therapy restores gut flora, effectively treating CDI and its symptoms.

Area of Science:

  • Microbiology
  • Gastroenterology
  • Infectious Diseases

Background:

  • Antibiotic overuse has increased Clostridium difficile infection (CDI) and antibiotic-resistant strains.
  • Recurrent CDI poses significant medical and economic challenges.
  • Standard antibiotic treatments for CDI can exacerbate gut dysbiosis.

Purpose of the Study:

  • To review fecal microbiota transplantation (FMT) as an alternative therapy for CDI.
  • To discuss the rationale, indications, and techniques of FMT for CDI.
  • To evaluate the benefits and complications of FMT in restoring gut microbiota.

Main Methods:

  • Review of existing literature on fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI).
  • Analysis of FMT's role in restoring colonic flora and eradicating C. difficile.
  • Examination of donor suitability, procedural risks, and patient acceptance.

Main Results:

  • FMT has a high success rate in resolving recurrent CDI and associated symptoms.
  • Restoring gut microbiota through FMT is an effective alternative to antibiotics.
  • Despite challenges like donor screening and patient aversion, FMT is gaining clinical acceptance.

Conclusions:

  • Fecal microbiota transplantation (FMT) is a viable and effective treatment for recurrent Clostridium difficile infection (CDI).
  • FMT addresses the underlying gut dysbiosis, offering a more sustainable solution than antibiotics.
  • Further research and standardization are needed to overcome barriers to widespread FMT adoption.

Related Concept Videos

Microbiota of the Large Intestine01:27

Microbiota of the Large Intestine

The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...
98
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
917
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
Introduction to the Human Microbiota01:22

Introduction to the Human Microbiota

Microorganisms colonize various regions of the human body, including the mouth, nasal passages, throat, stomach, intestines, urogenital tract, and skin. The total number of microbial cells is estimated to range from 10¹³ to 10¹⁴—comparable to, or exceeding, the number of human somatic cells. This host–microbiome relationship has led to the conceptualization of humans as supraorganisms, wherein microbial communities perform vital roles in development, immunity,...
209
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
61